文献速递血栓与止血

Fostamatinib治疗难治性免疫性血小板减少症的真实世界疗效与安全性:法国前瞻性多中心登记研究

Real-World Effectiveness and Safety of Fostamatinib in Difficult-to-Treat Immune Thrombocytopenia Patients. A Prospective, Multicenter Registry in France.
PubMed 文献 · Am J Hematol · 2026-01-08

法国2021年10月起用fostamatinib治疗成人慢性ITP,卫生当局要求开展3年前瞻性多中心登记以提供真实世界证据。164例患者纳入分析,中位年龄59岁,中位ITP病程7.2年,中位既往治疗数6种。第3、6、12、24个月缓解率分别为44.0%、41.9%、32.4%、20.0%,累计停药率分别为27.0%、44.6%、55.9%、76.2%,未观察到新安全性信号。

要点

  • fostamatinib在难治性ITP中3个月缓解率44.0%,随治疗时间延长缓解率下降。
  • 缓解者中超过60%同时使用TPO-RA等伴随治疗。
  • 43.3%患者用药期间发生出血,无致死性出血。

核心结论

  • fostamatinib联合TPO-RA应考虑用于难治性ITP患者。
  • 真实世界未观察到新的安全性信号。

研究设计与样本

  • 法国卫生当局要求的前瞻性、多中心、3年登记研究。
  • 共纳入164例成人慢性ITP患者,中位年龄59岁,55.5%为女性。
  • 84.1%有既往出血史,30例为继发性ITP,89.0%为慢性ITP。
  • 中位ITP病程7.2年,中位既往ITP治疗数为6种。

主要发现

  • 缓解率在第3个月为44.0%(70/159),第6个月为41.9%(62/148),第12个月为32.4%(44/136),第24个月为20.0%(21/105)。
  • 各终点缓解者中超过60.0%使用伴随治疗,主要为TPO-RA。
  • 各终点累计停药率分别为27.0%、44.6%、55.9%、76.2%。

关键数值与推荐

  • 缓解定义为持续暴露于fostamatinib且血小板计数≥30×10^9/L,且前4周内未使用救援治疗。

临床怎么用

  • 对难治性ITP可考虑fostamatinib联合TPO-RA治疗。
  • 用药期间需监测腹泻、动脉性高血压、血栓和感染等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fostamatinib is available in France since October 2021 for the treatment of adult chronic immune thrombocytopenia (ITP). French health authorities requested a 3-year, prospective, multicenter registry to provide real-world evidence about the effectiveness and safety of fostamatinib. Patients' characteristics, treatment response (ongoing exposure to fostamatinib and a platelet count ≥ 30 × 109/L with no rescue in the previous 4 weeks) after 3, 6, 12, and 24 months (M); bleeding; fostamatinib discontinuation; adverse drug reactions (ADRs) and other events of interest have been analyzed. In total, 164 patients were included (median age: 59 years; 55.5% women; 84.1% had previous bleeding; 30 had secondary ITP; 89.0% had chronic ITP). The median ITP duration was 7.2 years and the median number of previous ITP treatments was 6. The response rate was 44.0% (70/159) at M3, 41.9% (62/148) at M6, 32.4% (44/136) at M12 and 20.0% (21/105) at M24. Concomitant treatment (mostly TPO-RA) was used in > 60.0% of responders at each endpoint. The cumulative discontinuation rate at each endpoint was, respectively, 27.0%, 44.6%, 55.9%, and 76.2%. Seventy-one (43.3%) patients experienced at least one bleeding during fostamatinib exposure; none was fatal. One hundred adverse drug reactions (8 serious) were observed in 61 (36.7%) patients, including diarrhea in 28 (17.1%) patients, arterial hypertension in 17 (10.4%). Seven thrombosis (4.3%) and 40 infections (12 serious) were reported in 25 patients (15.2%), mostly in patients with known risk factors. In conclusion, fostamatinib in combination with TPO-RA should be considered in difficult-to-treat ITP patients. No new safety signal was observed.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Moulis G, Mahévas M, Viallard JF, et al. Real-World Effectiveness and Safety of Fostamatinib in Difficult-to-Treat Immune Thrombocytopenia Patients. A Prospective, Multicenter Registry in France. Am J Hematol. 2026. PMID: 41504185. doi:10.1002/ajh.70194

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。